10x Genomics Inc.

TXGUnited States

36 filed reports · 381 financial concepts · 12 earnings calls · 3 media appearances

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$643M

FY2025 · to Dec 31, 2025

up +5.2% vs $611M

10-K

Net income

-$43.5M

FY2025 · to Dec 31, 2025

a year earlier: -$183M

10-K

Operating income

-$61M

FY2025 · to Dec 31, 2025

a year earlier: -$195M

10-K

Latest quarter

Revenue

$151M

Q3 FY2026 · to Sep 30, 2026

up +1.1% vs $149M

10-Q

Net income

-$19.4M

Q3 FY2026 · to Sep 30, 2026

a year earlier: -$27.5M

10-Q

Operating income

-$16.1M

Q3 FY2026 · to Sep 30, 2026

a year earlier: -$32.2M

10-Q

Filed reports

36 reports · Sep 2019 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 14 guidance figures, 32 earnings-release figures, 34 commentary passages.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR223,956Sep 2019 to Sep 2026
Annual · 10-KSEC EDGAR73,351Dec 2019 to Dec 2025
Current · 8-KSEC EDGAR720Sep 2019 to Sep 2026

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q310-Q2026-09-302026-11-06377Open
FY2026 Q38-K2026-09-302026-11-056Open
FY2026 Q210-Q2026-06-302026-08-07238Open
FY2026 Q28-K2026-06-302026-08-064Open
FY2026 Q110-Q2026-03-312026-05-08234Open
FY202510-K2025-12-312026-02-13891Open
FY2025 Q310-Q2025-09-302025-11-07181Open
FY2025 Q210-Q2025-06-302025-08-08153Open
FY2025 Q110-Q2025-03-312025-05-09149Open
FY202410-K2024-12-312025-02-13439Open
FY2024 Q310-Q2024-09-302024-10-29165Open
FY2024 Q210-Q2024-06-302024-08-08151Open

Financial data

381 concepts · 7,327 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial375 concepts · 6,784 facts · Dec 2017 to Sep 2026

  • Accrued legal and related costs45 · Dec 2018 to Sep 2026
  • Stockholders equity (US GAAP)45 · Dec 2017 to Sep 2026
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value44 · Dec 2017 to Sep 2026
  • Gross profit (US GAAP)44 · Dec 2017 to Sep 2026
  • Net income loss44 · Dec 2017 to Sep 2026
  • Other comprehensive income loss net of tax portion attributable to parent44 · Dec 2017 to Sep 2026
  • Revenue44 · Dec 2017 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents43 · Dec 2017 to Sep 2026
  • Allocated share based compensation expense42 · Dec 2017 to Sep 2026
  • Comprehensive income net of tax42 · Dec 2017 to Sep 2026
  • Cost of revenue (US GAAP)42 · Dec 2017 to Sep 2026
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest42 · Dec 2017 to Sep 2026
  • Income tax expense benefit42 · Dec 2017 to Sep 2026
  • Investment income interest42 · Dec 2017 to Sep 2026
  • Nonoperating income expense42 · Dec 2017 to Sep 2026
  • Operating expenses (US GAAP)42 · Dec 2017 to Sep 2026
  • Operating income loss42 · Dec 2017 to Sep 2026
  • Other nonoperating income expense42 · Dec 2017 to Sep 2026
  • Research and development expense excluding acquired in process cost42 · Dec 2017 to Sep 2026
  • Selling general and administrative expense42 · Dec 2017 to Sep 2026
  • Accrued expenses and other current liabilities41 · Dec 2017 to Sep 2026
  • Capital expenditures incurred but not yet paid41 · Dec 2017 to Sep 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect41 · Dec 2017 to Sep 2026
  • Depreciation depletion and amortization41 · Dec 2017 to Sep 2026

Geography1 concept · 260 facts · Dec 2017 to Sep 2026

  • Revenue260 · Dec 2017 to Sep 2026

Product1 concept · 257 facts · Dec 2017 to Sep 2026

  • Revenue257 · Dec 2017 to Sep 2026

Guidance3 concepts · 18 facts · Nov 2019 to Nov 2026

  • Revenue Guidance14 · Nov 2019 to Nov 2026
  • Revenue Growth Guidance2 · Aug 2026
  • Revenue Growth Guidance (Adjusted (non-GAAP))2 · Nov 2026

KPI1 concept · 8 facts · Dec 2021 to Dec 2025

  • Deliveries8 · Dec 2021 to Dec 2025

Segments

517 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement geographical9 members · 260 facts

  • CN42 · Dec 2017 to Sep 2026
  • EMEA42 · Dec 2017 to Sep 2026
  • Asia Pacific38 · Dec 2017 to Sep 2026
  • Asia Pacific Excluding China31 · Mar 2020 to Sep 2026
  • US30 · Dec 2019 to Sep 2026
  • Americas24 · Dec 2021 to Sep 2026
  • Americas Excluding United States24 · Dec 2021 to Sep 2026
  • North America17 · Dec 2017 to Sep 2021
  • North America Excluding United States12 · Dec 2019 to Dec 2022

Product or service12 members · 257 facts

  • Consumables42 · Dec 2017 to Sep 2026
  • Service42 · Dec 2017 to Sep 2026
  • Instruments34 · Mar 2019 to Sep 2026
  • Spatial Consumables24 · Dec 2021 to Sep 2026
  • Spatial Instruments24 · Dec 2021 to Sep 2026
  • Chromium Consumables22 · Dec 2021 to Sep 2026
  • Chromium Instruments22 · Dec 2021 to Sep 2026
  • Licensing And Royalty Revenue14 · Dec 2023 to Sep 2026
  • Product And Service Revenue14 · Dec 2023 to Sep 2026
  • Instuments13 · Dec 2017 to Dec 2022
  • Single Cell Consumables3 · Dec 2023 to Dec 2025
  • Single Cell Instruments3 · Dec 2023 to Dec 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary89 claims from 12 reports · Sep 2024 to Sep 2026
  • Management discussion (MD&A) commentary171 claims from 9 reports · Sep 2024 to Sep 2026
  • Risk-factor changes139 claims from 6 reports · Dec 2020 to Dec 2025
  • Risk factors456 risks from 7 annual reports · 2019 to 2025

Earnings calls

12 calls · Feb 2024 to Nov 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-11-05
  • FY2026 Q22026-08-06
  • FY2026 Q12026-05-07
  • FY2025 Q42026-02-12
  • FY2025 Q32025-11-06
  • FY2025 Q22025-08-09
  • FY2025 Q12025-05-08
  • FY2024 Q42025-02-12
  • FY2024 Q32024-10-29
  • FY2024 Q22024-08-08
  • FY2024 Q12024-04-30
  • FY2023 Q42024-02-15

Executive media

3 appearances

Podcasts, interviews and conference appearances by the company's executives, with their claims.

  • Other appearances2 · Sep 2022 to Apr 2026
  • TV interviews1 · Oct 2020

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of 10x Genomics Inc. (TXG) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.